H.C. Wainwright analyst Joseph Pantginis adjusted the firm’s price target on Rigel Pharmaceuticals to $57 from $15 and keeps a Buy rating on the shares to reflect the one-for-20 reverse split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
- RIGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Rigel Pharmaceuticals trading halted, news pending
- Rigel Pharmaceuticals announces 1-for-10 reverse stock split